BioSpace News Archive

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer.

Precedence Research, the global over the counter (OTC) drugs market was evaluated at US$ 125.28 billion in 2023 and is expected to attain around US$ 229.01 billion by 2033, growing at a CAGR of 6.51% from 2024 to 2033.

Findings from the CATALYST study reveal that hypercortisolism may be a significant factor for why type 2 diabetes remains difficult to control for many patients.

Findings from the ATTEMPT study, showed that a low-dose of SGLT2 inhibitor could safely be given to youth and adolescents with type 1 diabetes to improve kidney function and glycemic management.

A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc., a leader in genetic testing and precision medicine.

Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO®.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that results from the prevalence phase of its CATALYST study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented at the American Diabetes Association’s 84th Scientific Sessions.

GRAIL, Inc. announced its spin-off from Illumina is complete, and GRAIL will be listed and commence regular-way trading on the Nasdaq under the symbol “GRAL” as of tomorrow, June 25, 2024.

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) today announced its financial results for the fiscal fourth quarter and year ended March 31, 2024, and provided a corporate update.